未登录

L

Lu Xie

shanghai academy of science & technology

H指数:16

被引数:1,642

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SVNeoPP: A Workflow for Structural-Variant-Derived Neoantigen Prediction and Prioritization Using Multi-Omics Data

SVNeoPP：一种利用多组学数据进行的结构变异衍生新抗原预测和优先级排序的工作流程

IF3.5

2026-03-230

OAAI

Single-Cell Multi-Tissue T Cell Clonal Dynamics Reveal Distinct Immune Coercion Landscapes in MSI and MSS Colorectal Cancer

单细胞多组织T细胞克隆动力学揭示MSI和MSS结直肠癌中独特的免疫胁迫景观

International Journal of Molecular Sciences

IF4.9

2026-03-160

OA

ProTCR: a protein language model-driven framework for decoding TCR-antigen recognition toward precision immunotherapies

ProTCR：一种基于蛋白质语言模型驱动的框架，用于解码TCR-抗原识别以实现精准免疫疗法

Briefings in Bioinformatics

IF7.7

2026-01-010

PRE

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study

阿帕替尼联合异环磷酰胺和依托泊苷与异环磷酰胺和依托泊苷在晚期骨肉瘤患者中的比较（OAIE/PKUPH-sarcoma 11）：一项随机II期研究

Nature Communications

IF15.7

2025-11-250

OAAI

Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial

抗PD-1抗体联合安鲁木单抗与安鲁木单抗单药治疗难治性软骨肉瘤患者的比较：一项多中心、非随机Ⅱ期FLAIL-C临床试验

IF11.8

2025-08-280

OAAI

Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers

JOURNAL OF HEMATOLOGY & ONCOLOGY

IF40.4

2024-12-180

OAAI

Question on the Use of BMI ≥25 kg/m2 to Define Obesity to Analyze the Incidence and Risk Factors of Hepatic Steatosis and Hepatic Fibrosis in the Chinese Population

GASTROENTEROLOGY

IF25.1

2024-03-010

OA

The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma

IF3.4

2024-02-031

OAAI

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

IF3.4

2023-09-156

OAAI

Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma

IF6.4

2023-05-276

OAAI

Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung

IF3.6

2023-05-011

OAAI

Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial

CLINICAL CANCER RESEARCH

IF10.2

2023-01-095

OA

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

CLINICAL CANCER RESEARCH

IF10.2

2022-06-2912

OAAI

Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy

全身治疗完全缓解后，具有广泛肺/胸膜转移的尤文肉瘤患者的长期预后和复发模式

IF3.4

2022-05-061

OAAI

Novel anti-PD-L1 antibody TQB2450 (T) in combination with anlotinib (A) in patients with advanced soft tissue sarcoma (STS), the results from the expanded sample size and updated data

ANNALS OF ONCOLOGY

IF65.4

2021-12-010

OA

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience

FRONTIERS IN ONCOLOGY

IF3.3

2021-07-226

OAAI

Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China

IF3.4

2021-03-314

OAAI

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

IF10.1

2021-03-01311

PREAI

Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study

ANNALS OF ONCOLOGY

IF65.4

2020-09-011

OAAI

Dynamic changes in quality of life and Q-TWiST analysis for Ewing sarcoma patients following anlotinib and irinotecan: A combination of phase Ib and II trial

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI